Kailera Therapeutics, Inc. - Common stock (NQ:KLRA)

10.84 +0.45 (+4.33%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kailera Therapeutics, Inc. - Common stock

Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy ↗

September 30, 2026

Could this be what Novo needs to turn things around?

Via The Motley Fool

Topics Initial Public Offering

Kailera Therapeutics to Participate in September Investor Conferences

September 16, 2026

From Kailera Therapeutics, Inc.

Via GlobeNewswire

2 GLP-1 Stocks That Could Double Your Money by 2031 ↗

August 16, 2026

They are fairly risky, but their potential upside is massive.

Via The Motley Fool

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 12, 2026

From Kailera Therapeutics, Inc.

Via GlobeNewswire

Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer

August 11, 2026

Veteran technical operations executive to lead manufacturing and supply chain strategy as company advances late-stage obesity pipeline toward commercialization

From Kailera Therapeutics, Inc.

Via GlobeNewswire

2 Beaten-Down GLP-1 Stocks to Buy on the Dip ↗

July 15, 2026

Don't wait until clinical milestones send their share prices soaring.

Via The Motley Fool

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535

July 07, 2026

From Kailera Therapeutics, Inc.

Via GlobeNewswire

Pfizer's CEO Says His Company Has a "Very Big Balance Sheet" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant ↗

July 02, 2026

Could this be the secret to Pfizer's rebound strategy?

Via The Motley Fool

3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗

June 16, 2026

All three could become highly prominent biotech companies within 10 years.

Via The Motley Fool

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock? ↗

June 12, 2026

It's important to consider your comfort with risk before diving in.

Via The Motley Fool

Topics Initial Public Offering

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

May 28, 2026

From Kailera Therapeutics, Inc.

Via GlobeNewswire

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

May 26, 2026

From Kailera Therapeutics, Inc.

Via GlobeNewswire

Is Kailera Therapeutics a Buy After Its Sizzling IPO? ↗

May 16, 2026

There's a new challenger to the more established players in the weight-loss drug space.

Via The Motley Fool

Topics Initial Public Offering

A Kailera Therapeutics (KLRA) Insider Scooped up an Additional 500,000 Shares for $8.0 Million ↗

April 27, 2026

Kailera Therapeutics, a clinical-stage biotech focused on obesity treatments, just reported a notable insider buy in recent SEC filings.

Via The Motley Fool

Topics Regulatory Compliance

Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

April 20, 2026

From Kailera Therapeutics, Inc.

Via GlobeNewswire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.